White Paper Archives - WuXi Biology

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Screening Strategies for Molecular Glue Discovery

Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...

Streamlining Gene Therapy with AAVs

Gene therapies are enabling a rapid expansion in the scope of treatable disease. Adeno-associated viruses (AAVs) are particularly advantageous delivery...

Emerging Drug Discovery Strategies for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

Oligonucleotide Therapeutics: Drug Discovery Through Tightly Coupled Chemistry and Biology

Designing effective oligonucleotide therapeutics for clinical applications involves understanding both the chemistry and biology of nucleic acids. In this white...

Knowledge Library